Related Experiment Video
Updated: Jun 11, 2025
Co-analysis of Brain Structure and Function using fMRI and Diffusion-weighted Imaging
Published on: November 8, 2012
The QIBA Profile for Diffusion-Weighted MRI: Apparent Diffusion Coefficient as a Quantitative Imaging Biomarker
Michael A Boss1, Dariya Malyarenko1, Savannah Partridge1
1From the Center for Research and Innovation, American College of Radiology, 50 S 16th St, Philadelphia, PA 19102 (M.A.B.); Department of Radiology, University of Michigan, Ann Arbor, Mich (D.M., T.L.C.); Department of Radiology, University of Washington, Seattle, Wash (S.P.); Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio (N.O.); Departments of Medical Physics and Radiology, Memorial Sloan Kettering Cancer Center, New York, NY (A.S.D.); The Institute of Cancer Research, London, UK (J.M.W., N.M.d.S.); The Royal Marsden NHS Foundation Trust, London, UK (J.M.W., N.M.d.S.); Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Tex (C.D.F.); CaliberMRI, Boulder, Colo (K.M.); Department of Radiology, University of Alabama at Birmingham, Birmingham, Ala (V.M.); Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, Calif (M.O., L.J.W.); Aim Medical Imaging, Vancouver, Canada (R.A.); Mallinckrodt Institute of Radiology, Washington University School of Medicine, St Louis, Mo (T.A.); and Department of Radiology, Weill Cornell Medical College, New York, NY (D.J.M.).
Abstract:
The apparent diffusion coefficient (ADC) provides a quantitative measure of water mobility that can be used to probe alterations in tissue microstructure due to disease or treatment. Establishment of the accepted level of variance in ADC measurements for each clinical application is critical for its successful implementation. The Diffusion-Weighted Imaging Biomarker Committee of the Quantitative Imaging Biomarkers Alliance (QIBA) has recently advanced the ADC Profile from the consensus to clinically feasible stage for the brain, liver, prostate, and breast. This profile distills multiple studies on ADC repeatability and describes detailed procedures to achieve stated performance claims on an observed ADC change within acceptable confidence limits. In addition to reviewing the current ADC Profile claims, this report has used recent literature to develop proposed updates for establishing metrology benchmarks for mean lesion ADC change that account for measurement variance. Specifically, changes in mean ADC exceeding 8% for brain lesions, 27% for liver lesions, 27% for prostate lesions, and 15% for breast lesions are claimed to represent true changes with 95% confidence. This report also discusses the development of the ADC Profile, highlighting its various stages, and describes the workflow essential to achieving a standardized implementation of advanced quantitative diffusion-weighted MRI in the clinic. The presented QIBA ADC Profile guidelines should enable successful clinical application of ADC as a quantitative imaging biomarker and ensure reproducible ADC measurements that can be used to confidently evaluate longitudinal changes and treatment response for individual patients.
